Hope of fresh treatment for seven cancers after single antibody is found to shrink tumours from all of them
00:57 GMT, 27 March 2012
A drug that helps the immune system to break down cancerous tumours has been developed.
It has worked on breast, bowel, prostate, ovarian, brain, bladder and liver cancers, while previous studies show it can also be used to fight some blood cancers.
If given early, the drug could even be a cure, researchers say.
The Y-shaped human antibody works by unmasking the cancer cells to the body's disease-fighting white blood cells
The antibody has so far been tested only on mice, but researchers hope to give it to people within two years.
Its effectiveness centres on a
protein called CD47, which is found on the surface of cancer cells in
high quantities. The protein prevents them from being engulfed and eaten
by immune cells called macrophages.
The drug masks the so-called
‘don’t-eat-me signal’, allowing the immune system to attack the cancer –
a goal of many researchers for decades.
Breakthrough: Professor Irving Weissman from Stanford University who made the finding
Tests on cells in the lab and on mice
showed it to work on a broad range of cancers and with minimal
side-effects. Given to mice with human tumours, the antibody made them
shrink and, in some cases, disappear.
The journal Proceedings of the National Academy of Sciences adds that the drug ‘dramatically’ increased survival rates.
Researcher Dr Irving Weissman, from
the Stanford University School of Medicine in California, said:
‘Blocking this “don’t-eat-me” signal inhibits the growth in mice of
nearly every human cancer we tested, with minimal toxicity.
‘This shows conclusively that this protein, CD47, is a legitimate and promising target for human cancer therapy.’
Dr Weissman said that when used on
small tumours, the drug is ‘potentially curative’ – but stressed that
for some of the mice it did not work at all.
He added that there was now enough evidence to ‘move forward quickly but cautiously’ into human trials.
However, the need for extensive proof
that the drug is safe as well as effective means that its widespread
use is about a decade away.
Professor Philip Ashton-Rickardt, an
expert in immunology funded by Cancer Research UK, said the research
could lead to new treatments.
‘Particularly exciting is the
possibility that this approach could be used to tackle cancer cells that
are resistant to traditional treatments such as chemotherapy and
radiotherapy,’ he said.
‘But clinical trials are needed to find out whether it will benefit patients.’